A randomized, double-dummy, double-blind/open, parallel-group, phase-III, multicentre, 7-month study to assess the efficacy and safety of Symbicort Turbuhaler (budesonide/formoterol; 160/4.5 mcg delivered dose) given either as standard therapy (2 inhal. b.i.d.) or with an adjustable dosing regimen (1, 2 or 4 inhal. b.i.d.) versus Seretide Diskus (salmeterol/fluticasone; 50/250 mcg metered dose) given as standard therapy (1 inhal. b.i.d.) in adult and adolescent asthmatic patients.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.